Yeast-derived nanoparticles remodel the immunosuppressive microenvironment in tumor and tumor-draining lymph nodes to suppress tumor growth

Jialu Xu, Qingle Ma, Yue Zhang, Ziying Fei, Yifei Sun, Qin Fan, Бо Лю, Jinyu Bai, Yue Yu, Jianhong Chu, Jingrun Chen, Chao WangNature Communications 2022 · DOI

TL;DR

Researchers have developed yeast-derived nanoparticles (YCW NPs) that effectively remodel the tumor microenvironment and tumor-draining lymph nodes (TDLNs) to suppress tumor growth. The size of these nanoparticles is crucial, with smaller ones showing superior accumulation in TDLNs and enhanced anti-tumor immunity, especially when combined with PD-L1 blockade.

What Problem Does This Paper Address?

Cancer immunotherapy, particularly using immune checkpoint inhibitors (ICIs), has shown promise but faces limitations. Many tumors, termed "cold tumors," are resistant to these therapies due to a lack of immune cell infiltration and a highly immunosuppressive tumor microenvironment (TME). Microbe-based immunotherapies offer a potential solution, but live microbes carry risks of infection and can have unsatisfactory clinical outcomes. This paper addresses the need for safer and more effective microbe-derived immunotherapies by developing yeast-derived nanoparticles (YCW NPs) that can modulate the TME and TDLNs to boost anti-tumor immunity.

Methods

The researchers fabricated YCW NPs of different sizes (~50 nm, ~200 nm, and ~500 nm) using differential centrifugation from yeast cell walls. They characterized these nanoparticles using SEM, TEM, DLS, and SDS-PAGE. The study involved in vitro experiments with dendritic cells (DCs), macrophages, and T cells to assess cellular uptake, maturation, and cytokine production. In vivo studies utilized a melanoma mouse model (B16-luc) to evaluate tumor growth inhibition, immune cell infiltration in tumors and TDLNs, and the efficacy of YCW NPs alone and in combination with PD-L1 blockade. A mathematical percolation model was employed to explain the size-dependent distribution of YCW NPs in TDLNs.

Datasets

Not discussed in the paper. The study primarily relies on in vitro cell cultures and in vivo animal models.

Key Insights and Ideas

  • Size Matters for Nanoparticle Immunotherapy: The study reveals a critical inverse correlation between YCW NP size and anti-tumor efficacy. Smaller nanoparticles are significantly more effective.
  • TDLN Accumulation is Key: Smaller YCW NPs preferentially accumulate in tumor-draining lymph nodes (TDLNs), which are crucial for initiating adaptive immune responses. This targeted accumulation is hypothesized to be the primary driver of their enhanced efficacy.
  • Remodeling the Immunosuppressive Microenvironment: YCW NPs, particularly the smaller ones, effectively remodel both the tumor microenvironment and TDLNs by increasing effector immune cell populations and improving their functional orientation.
  • A Percolation Model for Nanoparticle Distribution: The authors introduce a mathematical percolation model to explain how nanoparticle size influences their ability to navigate lymphatic vessels and accumulate in TDLNs, providing a theoretical basis for the observed size-dependent effects.
  • Synergy with Immune Checkpoint Blockade: Combining YCW NPs with PD-L1 blockade leads to complete tumor regression and significantly improved survival in mice, highlighting a potent therapeutic strategy.
  • Biosafety and Tunability: Yeast-derived nanoparticles offer a promising alternative to live microbes due to their lack of reproductive ability and tunable size, suggesting potential for clinical translation.

Key Results

  • Tumor Growth Inhibition: All sizes of YCW NPs inhibited tumor growth, but small YCW NPs (~50 nm) showed the greatest efficacy.
  • TDLN Accumulation: Small YCW NPs demonstrated significantly higher accumulation in TDLNs compared to medium and large YCW NPs.
  • Immune Cell Modulation: Small YCW NPs treatment led to increased infiltration of CD8+ T cells and CD4+ T cells in tumors and improved DC maturation in both tumors and TDLNs. They also reduced immunosuppressive cells like Tregs, MDSCs, and TAMs.
  • Combination Therapy Efficacy: The combination of small YCW NPs and PD-L1 blockade achieved complete tumor regression in 100% of treated mice and significantly prolonged survival.
  • Systemic Anti-Tumor Response: The combination therapy also induced a systemic immune response, leading to the regression of distant tumors and inhibition of lung metastasis.
  • Safety Profile: YCW NPs showed minimal cytotoxicity in vitro and the combination therapy was well-tolerated in mice, with no significant weight loss or organ damage.

Limitations and Future Work

The authors acknowledge that while they studied the role of size, other properties of YCW NPs, such as charge density, could also influence tumor growth and immune cell activation and warrant further investigation. They also suggest that while yeast-derived components like proteins and nucleic acids may contribute to TME remodeling, their specific roles require further exploration. The study primarily focused on melanoma and CT26 models; future work could explore the efficacy of this approach in a broader range of cancer types. The mathematical percolation model provides a theoretical framework, but further experimental validation and refinement could be beneficial.

Summary updated

Abstract

Microbe-based cancer immunotherapy has recently emerged as a hot topic for cancer treatment. However, serious limitations remain including infection associated side-effect and unsatisfactory outcomes in clinic trials. Here, we fabricate different sizes of nano-formulations derived from yeast cell wall (YCW NPs) by differential centrifugation. The induction of anticancer immunity of our formulations appears to inversely correlate with their size due to the ability to accumulate in tumor-draining lymph node (TDLN). Moreover, we use a percolation model to explain their distribution behavior toward TDLN. The abundance and functional orientation of each effector component are significantly improved not only in the microenvironment in tumor but also in the TDLN following small size YCW NPs treatment. In combination with programmed death-ligand 1 (PD-L1) blockade, we demonstrate anticancer efficiency in melanoma-challenged mice. We delineate potential strategy to target immunosuppressive microenvironment by microbe-based nanoparticles and highlight the role of size effect in microbe-based immune therapeutics.
BibTeX
@inproceedings{xu2022yeast,
  author = {Jialu Xu and Qingle Ma and Yue Zhang and Ziying Fei and Yifei Sun and Qin Fan and Бо Лю and Jinyu Bai and Yue Yu and Jianhong Chu and Jingrun Chen and Chao Wang},
  title = {{Yeast-derived nanoparticles remodel the immunosuppressive microenvironment in tumor and tumor-draining lymph nodes to suppress tumor growth}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-021-27750-2},
}
Figure